Calcitonin gene-related peptide in migraine: from pathophysiology to treatment
Santos-Lasaosa S (1), Belvís R (2), Cuadrado ML (3), Díaz-Insa S (4), Gago-Veiga A (5), Guerrero-Peral AL (6), Huerta M (7), Irimia P (8), Láinez JM (9), Latorre G (10), Leira R (11), Pascual J (12), Porta-Etessam J (3), Sánchez Del Río M (13), Viguera J (14), Pozo-Rosich P (15).
It has been observed in recent years that levels of such molecules as calcitonin gene-related peptide (CGRP) and, to a lesser extent, the pituitary adenylate cyclase-activating peptide are elevated during migraine attacks and in chronic migraine, both in the cerebrospinal fluid and in the serum. Pharmacological reduction of these proteins is clinically significant, with an improvement in patients' migraines. It therefore seems logical that one of the main lines of migraine research should be based on the role of CGRP in the pathophysiology of this entity.
The Spanish Society of Neurology's Headache Study Group decided to draft this document in order to address the evidence on such important issues as the role of CGRP in the pathophysiology of migraine and the mechanism of action of monoclonal antibodies and gepants; and to critically analyse the results of different studies and the profile of patients eligible for treatment with monoclonal antibodies, and the impact in terms of pharmacoeconomics.
The clinical development of gepants, which are CGRP antagonists, for the acute treatment of migraine attacks, and CGRP ligand and receptor monoclonal antibodies offer promising results for these patients.
CITATION Neurologia. 2019 Jul 17. pii: S0213-4853(19)30075-1. doi: 10.1016/j.nrl.2019.03.013